DNA clues could forecast steroid relapse in PMR

NCT ID NCT07748195

Not yet recruiting Knowledge-focused Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study investigates whether DNA methylation patterns in blood immune cells can predict which patients with Polymyalgia Rheumatica (PMR) will relapse when corticosteroid treatment is tapered. Researchers will analyze blood samples from 50 PMR patients to see if specific immune cell changes correlate with relapse. The goal is to develop a simple, affordable blood test that could guide treatment decisions and reduce the risk of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DNA methylation analysis of blood samples
What this could lead to: If successful, this could lead to a blood test that predicts which PMR patients will relapse when steroids are tapered, enabling personalized treatment plans.
What could go wrong: This is an observational study with a relatively small sample size. The findings may not be generalizable, and the predictive markers may not prove reliable in broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA (PMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polymyalgia rheumatica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYMYALGIA RHEUMATICA (PMR)

More trials for these conditions

Other studies related to the condition(s) this trial covers.